ALDX Aldeyra Therapeutics, Inc. Stock Quote

ALDX [NASD]

Index	-	P/E	-	EPS (ttm)	-1.02	Insider Own	1.70%	Shs Outstand	45.63M	Perf Week	-3.40%
Market Cap	690.88M	Forward P/E	-	EPS next Y	-1.14	Insider Trans	367.23%	Shs Float	39.44M	Perf Month	2.05%
Income	-39.00M	PEG	-	EPS next Q	-0.24	Inst Own	60.40%	Short Float	11.00%	Perf Quarter	-0.50%
Sales	-	P/S	-	EPS this Y	50.70%	Inst Trans	39.70%	Short Ratio	1.87	Perf Half Y	63.51%
Book/sh	2.76	P/B	4.32	EPS next Y	-14.00%	ROA	-39.90%	Target Price	-	Perf Year	159.13%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-50.70%	52W Range	3.95 - 15.95	Perf YTD	73.76%
Dividend	-	P/FCF	-	EPS past 5Y	4.60%	ROI	-	52W High	-25.27%	Beta	1.75
Dividend %	-	Quick Ratio	13.30	Sales past 5Y	-	Gross Margin	-	52W Low	201.77%	ATR	0.52
Employees	11	Current Ratio	13.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	45.66	Volatility	3.94% 4.03%
Optionable	Yes	Debt/Eq	0.12	EPS Q/Q	26.80%	Profit Margin	-	Rel Volume	0.61	Prev Close	12.15
Shortable	Yes	LT Debt/Eq	0.08	Earnings	May 06 BMO	Payout	-	Avg Volume	2.32M	Price	11.92
Recom	1.50	SMA20	-2.20%	SMA50	-1.30%	SMA200	22.33%	Volume	1,410,581	Change	-1.89%

Feb-08-21

Initiated

H.C. Wainwright

Buy

$26

Dec-16-20

Initiated

Berenberg

Buy

$32

Oct-30-20

Initiated

Jefferies

Buy

$24

Oct-16-20

Initiated

BTIG Research

Buy

$29

Sep-22-20

Initiated

Alliance Global Partners

Buy

$32

May-12-20

Initiated

Oppenheimer

Outperform

$12

Dec-04-18

Initiated

Citigroup

Buy

$23

Sep-26-18

Reiterated

Cantor Fitzgerald

Overweight

$23 → $30

Sep-13-18

Initiated

Janney

Buy

Jan-26-18

Initiated

Seaport Global Securities

Buy

$13

Sep-26-16

Initiated

H.C. Wainwright

Buy

$18

Jul-01-16

Initiated

Stifel

Buy

$16

Jul-01-15

Initiated

Canaccord Genuity

Buy

$16

Mar-25-15

Initiated

Chardan Capital Markets

Buy

$16

Mar-20-15

Reiterated

H.C. Wainwright

Buy

$13 → $14

Nov-18-14

Initiated

H.C. Wainwright

Buy

$13

Jun-19-14

Initiated

Aegis Capital

Buy

$35

May-27-21 08:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference Business Wire
May-06-21 09:31PM	Aldeyra Therapeutics (ALDX) Q1 2021 Earnings Call Transcript Motley Fool
07:00AM	Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights Business Wire
06:15AM	Aldeyra Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Apr-29-21 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2021 Financial Results and Discuss Recent Business Highlights Business Wire -10.23%
Apr-28-21 06:31PM	Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock Business Wire -6.20%
12:53PM	Why Aldeyra Therapeutics Stock Is Sinking Today Motley Fool
06:10AM	Aldeyra Seeks To Raise $125M Via Equity To Support Reproxalap US Application Benzinga
Apr-27-21 04:01PM	Aldeyra Therapeutics, Inc. Announces Proposed $125 Million Public Offering of Common Stock Business Wire +33.66%
11:06AM	Why Aldeyra Therapeutics Stock Is Soaring Today Motley Fool
07:40AM	Aldeyra Therapeutics Stock Is Trading Higher On Acing Allergic Conjunctivitis Study With Reproxalap Benzinga
07:00AM	Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis Business Wire
Apr-26-21 04:05PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE Clinical Trial Business Wire
Mar-11-21 07:00PM	Aldeyra Therapeutics (ALDX) Q4 2020 Earnings Call Transcript Motley Fool
07:00AM	Aldeyra Therapeutics Reports Full-Year 2020 Financial Results and Recent Business Highlights Business Wire
05:15AM	Aldeyra Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-10-21 08:00AM	Aldeyra Therapeutics to Present at the OIS Dry Eye Innovation Showcase on March 11, 2021 Business Wire
Mar-09-21 08:34AM	Why Earnings Season Could Be Great for Aldeyra Therapeutics (ALDX) Zacks +9.01%
Mar-04-21 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2020 Financial Results and Discuss Recent Business Highlights Business Wire -6.21%
Mar-02-21 08:00AM	Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences Business Wire
Feb-18-21 08:00AM	Aldeyra Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference Business Wire -6.44%
Feb-07-21 11:18PM	Could The Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ownership Structure Tell Us Something Useful? Simply Wall St.
Feb-04-21 08:00AM	Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Design Business Wire +5.85%
Jan-20-21 07:00AM	Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire -7.03%
Jan-13-21 09:36PM	Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock Business Wire -5.83%
04:01PM	Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock Business Wire
Jan-08-21 08:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect 2021 Virtual Conference Business Wire +21.72%
Jan-07-21 07:00AM	Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease Business Wire +26.42%
Jan-06-21 04:30PM	Aldeyra Therapeutics to Host Conference Call and Webcast to Discuss Top-Line Symptom, Redness, and Schirmers Test Results from Run-in Cohort of Phase 3 TRANQUILITY Trial Business Wire
Dec-22-20 08:00AM	Aldeyra Therapeutics Announces Confirmation of Antiviral Activity of ADX-1612 Business Wire -7.63%
Dec-17-20 08:00AM	Aldeyra Therapeutics Announces Initiation of Phase 2 Clinical Trials of ADX-629, a First-in-Class Orally Administered RASP Inhibitor, for the Treatment of COVID-19, Atopic Asthma, and Psoriasis Business Wire
Dec-16-20 09:18AM	Is ALDX A Good Stock To Buy Now? Insider Monkey +5.81%
Dec-08-20 08:00AM	Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Disease Business Wire
Nov-13-20 08:00AM	Aldeyra Therapeutics to Participate in the Jefferies and A.G.P./Alliance Global Partners Virtual Investor Conferences Business Wire
Nov-10-20 05:45AM	Are Insiders Buying Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Stock? Simply Wall St.
Nov-05-20 07:00AM	Aldeyra Therapeutics Announces Third-Quarter 2020 Financial Results and Provides Corporate Update Business Wire
06:15AM	Aldeyra Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-04-20 08:00AM	Aldeyra to Participate in the American Academy of Ophthalmology Eyecelerator 2020 Virtual Conference on Friday, November 6 Business Wire
Oct-30-20 09:22PM	Aldeyra Has 'Catalayst-Rich' 12 Months Ahead, Jefferies Says In Bullish Initiation Benzinga +5.86%
Oct-29-20 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2020 Financial Results and Corporate Update Business Wire
Oct-22-20 08:00AM	Aldeyra to Present New Reproxalap Data from Phase 2 Clinical Trial in Allergic Conjunctivitis at American Academy of Ophthalmology 2020 Annual Meeting Business Wire +6.90%
Oct-16-20 04:20PM	Why Aldeyra Therapeutics Stock Soared Today Motley Fool +18.08%
Oct-13-20 02:38PM	Hedge Funds Have Never Been This Bullish On Aldeyra Therapeutics Inc (ALDX) Insider Monkey
Oct-02-20 11:30AM	Has Aldeyra Therapeutics (ALDX) Outpaced Other Medical Stocks This Year? Zacks
Sep-30-20 07:55AM	4 Small Drug Stocks to Look Out For Amid Coronavirus Uncertainty Zacks
Sep-29-20 10:30AM	Oppenheimer: These 2 Stocks Are Poised to Surge by Over 100% TipRanks +5.02%
Sep-16-20 11:30AM	Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? Zacks
08:00AM	Aldeyra to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Business Wire
Sep-10-20 08:00AM	Aldeyra to Present at Cantor and H.C. Wainwright Virtual Investor Conferences Business Wire +5.12%
Sep-09-20 08:00AM	Aldeyra Receives Study May Proceed Letter from FDA to Initiate Clinical Trial of ADX-629 in COVID-19 Patients Business Wire +9.51%
Sep-03-20 08:00AM	Aldeyra to Participate in Citis 15th Annual BioPharma Virtual Conference Business Wire
Aug-25-20 11:30AM	Has Aldeyra Therapeutics (ALDX) Outpaced Other Medical Stocks This Year? Zacks
Aug-12-20 12:00PM	Aldeyra Therapeutics, Inc. (ALDX) Upgraded to Buy: Here's What You Should Know Zacks
Aug-06-20 10:09AM	Aldeyra's (ALDX) Q2 Earnings Beat Estimates, Pipeline in Focus Zacks -9.38%
07:00AM	Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update Business Wire
Aug-04-20 10:07AM	Aldeyra (ALDX) to Report Q2 Earnings: What's in the Offing? Zacks
08:00AM	Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences Business Wire
Jul-30-20 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second-Quarter 2020 Financial Results and Corporate Update Business Wire +8.53%
Jul-14-20 08:00AM	Aldeyra Therapeutics Announces Stock Sales to Perceptive Advisors and Avidity Partners Business Wire +21.28%
04:32AM	Aldeyra Spikes 10% In Pre-Market On New Perceptive Stake SmarterAnalyst
Jul-13-20 04:05PM	Aldeyra Therapeutics to Present at the OIS Virtual Public Company Showcase on July 16, 2020 Business Wire
Jul-07-20 09:28PM	Aldeyra Therapeutics Inc (ALDX): Hedge Funds In Wait-and-See Mode Insider Monkey +8.25%
08:00AM	Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease Business Wire
Jul-03-20 11:15AM	What Kind Of Investors Own Most Of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)? Simply Wall St.
Jul-01-20 09:36AM	Zynerba's Zygel Fails in Phase III Fragile X Syndrome Study Zacks
Jun-22-20 12:00PM	What Makes Aldeyra Therapeutics, Inc. (ALDX) a New Strong Buy Stock Zacks -6.86%
Jun-18-20 10:12AM	Aclaris Gets FDA Nod to Start Investigator-led Coronavirus Study Zacks
Jun-15-20 08:00AM	Aldeyra Therapeutics Receives Orphan Medicinal Product Designation from the European Commission for ADX-2191 Retinal Disease Program Business Wire
Jun-10-20 08:37PM	FibroGen (FGEN) in Focus: Stock Moves 6.5% Higher Zacks
Jun-07-20 06:28PM	Edited Transcript of ALDX earnings conference call or presentation 7-May-20 12:00pm GMT Thomson Reuters StreetEvents
Jun-04-20 08:00AM	Aldeyra Therapeutics Reaches Agreement with the US Food and Drug Administration for the Use of RASP as an Objective Sign for the Treatment of Dry Eye Disease Business Wire
Jun-03-20 09:04AM	Ironwood Pharmaceuticals (IRWD) Looks Good: Stock Adds 7.6% in Session Zacks -6.83%
08:00AM	Aldeyra Therapeutics to Present at the Jefferies Virtual Healthcare Conference Business Wire
May-27-20 09:49AM	3 Strong Buy Biotech Stocks Under $5 With Explosive Upside Potential TipRanks
May-20-20 05:24PM	Covid Report: This Biotech Says Its Coronavirus Drug Topped Remdesivir Investor's Business Daily +13.80%
08:12AM	The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test Benzinga
07:00AM	Aldeyra Therapeutics to Advance ADX-1612, an Investigational New HSP90 Inhibitor with Potential Nanomolar Potency Against SARS-CoV-2, to Clinical Testing for COVID-19; ADX-629 Accepted for BARDA CoronaWatch Meeting Business Wire
01:48AM	Aldeyra Explodes 30% After-Hours Ahead Of Covid-19 Update Today SmarterAnalyst
May-19-20 04:05PM	Aldeyra Therapeutics to Host Conference Call and Webcast to Provide COVID-19 Development Update Business Wire -8.57%
May-15-20 08:53AM	How Aldeyra (ALDX) Stock Stands Out in a Strong Industry Zacks +20.00%
May-14-20 10:14AM	Top Ranked Momentum Stocks to Buy for May 14th Zacks +5.63%
May-13-20 12:00PM	Aldeyra Therapeutics Inc (ALDX) Upgraded to Strong Buy: Here's What You Should Know Zacks +5.97%
08:17AM	Aldeyra's Shares March Higher, Can It Continue? Zacks
May-07-20 07:00AM	Aldeyra Therapeutics Reports First-Quarter 2020 Financial Results and Announces New Clinical Programs Business Wire
Apr-16-20 06:35AM	These Mass. companies are developing COVID-19 treatments and tests American City Business Journals
Apr-15-20 09:47AM	Company News for Apr 15, 2020 Zacks
Apr-14-20 08:00AM	Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629 Business Wire +27.82%
Apr-01-20 01:42AM	Edited Transcript of ALDX earnings conference call or presentation 12-Mar-20 12:00pm GMT Thomson Reuters StreetEvents -14.17%
Mar-24-20 12:00PM	What Makes Aldeyra Therapeutics, Inc. (ALDX) a New Buy Stock Zacks +22.87%
08:00AM	Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection Business Wire
Mar-18-20 06:13AM	Chair of the Board Richard Douglas Just Bought Shares In Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Simply Wall St. -15.35%
Mar-12-20 07:00AM	Aldeyra Therapeutics Reports Full-Year 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones Business Wire -13.26%
06:59AM	Aldeyra Announces Strategic Prioritization of Late-Stage Clinical Pipeline in Ocular Disease Business Wire
Mar-05-20 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Fourth-Quarter and Full-Year 2019 Financial Results and Corporate Update Business Wire -5.31%
Mar-03-20 08:00AM	Aldeyra Therapeutics to Present at the Oppenheimer & Co. 30th Annual Healthcare Conference Business Wire
Feb-24-20 08:00AM	Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day Business Wire
Feb-11-20 08:00AM	Aldeyra Therapeutics to Host 2020 Research & Development Day Business Wire
Jan-28-20 08:00AM	Aldeyra Therapeutics Appoints Dr. Paul Karpecki to Anterior Segment Scientific Advisory Board Business Wire
Jan-21-20 08:00AM	Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis Business Wire
Jan-14-20 08:00AM	Aldeyra Therapeutics Appoints Nancy Miller-Rich to Board of Directors Business Wire

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases and covid-19; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, allergy, and covid-19, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is headquartered in Lexington, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PERCEPTIVE ADVISORS LLC	10% Owner	May 03	Buy	12.50	1,200,000	15,000,000	9,903,879	May 04 05:55 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Jan 19	Buy	9.50	1,368,421	13,000,000	8,703,879	Jan 21 05:24 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Jan 08	Buy	9.34	550,000	5,137,668	7,335,458	Jan 11 09:53 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Jan 07	Buy	8.13	500,000	4,065,000	6,785,458	Jan 11 09:53 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Jul 09	Buy	4.25	3,200,000	13,600,000	6,285,458	Jul 13 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience